Alumis INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
ALMS
Alumis INCAlumis Inc. is set to launch its IPO, aiming to raise $274 million to fuel the clinical development of its TYK2 inhibitors, ESK-001 and A-005, targeting immune-mediated diseases.
NASDAQ
ALMS
Alumis INCAlumis Inc., a clinical-stage biopharmaceutical company, has filed an amended S-1 registration statement for its initial public offering, planning to use the proceeds to advance its TYK2 inhibitor programs and other research initiatives.
NASDAQ
ALMS
Alumis INCAlumis Inc., a clinical-stage biopharmaceutical company, has filed an S-1 registration statement for an IPO, planning to use the proceeds to further develop its TYK2 inhibitor programs and other preclinical candidates.